HighTower Advisors LLC Decreases Stock Holdings in iRadimed Corporation $IRMD

HighTower Advisors LLC cut its holdings in iRadimed Corporation (NASDAQ:IRMD) by 49.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 20,363 shares of the medical equipment provider’s stock after selling 19,998 shares during the quarter. HighTower Advisors LLC owned about 0.16% of iRadimed worth $1,981,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Baader Bank Aktiengesellschaft purchased a new stake in iRadimed in the fourth quarter valued at about $595,000. Ballentine Partners LLC purchased a new stake in iRadimed in the fourth quarter valued at about $211,000. RFG Advisory LLC purchased a new stake in iRadimed in the fourth quarter valued at about $1,594,000. James Investment Research Inc. purchased a new stake in iRadimed in the fourth quarter valued at about $239,000. Finally, Cornerstone Investment Partners LLC purchased a new stake in iRadimed in the fourth quarter valued at about $224,000. 92.34% of the stock is currently owned by hedge funds and other institutional investors.

iRadimed Stock Up 1.5%

Shares of NASDAQ:IRMD opened at $92.05 on Tuesday. iRadimed Corporation has a 52-week low of $55.11 and a 52-week high of $107.90. The stock has a market cap of $1.18 billion, a price-to-earnings ratio of 50.30 and a beta of 0.90. The business has a 50-day moving average price of $91.71 and a 200-day moving average price of $95.47.

iRadimed (NASDAQ:IRMD) last posted its earnings results on Friday, May 1st. The medical equipment provider reported $0.49 EPS for the quarter, topping the consensus estimate of $0.46 by $0.03. The firm had revenue of $21.98 million for the quarter, compared to analyst estimates of $21.32 million. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. As a group, equities analysts anticipate that iRadimed Corporation will post 1.52 EPS for the current fiscal year.

iRadimed Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, May 29th. Investors of record on Friday, May 15th were issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend was Friday, May 15th. iRadimed’s dividend payout ratio (DPR) is 43.72%.

Insider Buying and Selling

In related news, CEO Roger E. Susi sold 2,500 shares of the firm’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $87.88, for a total transaction of $219,700.00. Following the sale, the chief executive officer directly owned 2,172,500 shares of the company’s stock, valued at $190,919,300. This trade represents a 0.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 67,500 shares of company stock worth $6,318,853 over the last quarter. 36.80% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts have commented on IRMD shares. Lake Street Capital reiterated a “buy” rating and issued a $120.00 price target on shares of iRadimed in a research note on Wednesday, February 11th. Roth Mkm reiterated a “buy” rating and issued a $120.00 price target on shares of iRadimed in a research note on Tuesday, February 10th. Freedom Capital upgraded iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. Finally, Weiss Ratings cut iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a research note on Wednesday, May 20th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $120.00.

iRadimed Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.